Abstract:Background: In the ongoing battle against breast cancer, a leading cause of cancer-related mortality among women globally, the urgent need for innovative prognostic markers and therapeutic targets is undeniable. This study pioneers an advanced methodology by integrating machine learning techniques to unveil a vascular mimicry signature, offering predictive insights into breast cancer outcomes. Vascular mimicry refers to the phenomenon where cancer cells mimic blood vessel formation absent of endothelial cells, a trait associated with heightened tumor aggression and diminished response to conventional treatments. Methods: The study's comprehensive analysis spanned data from over 6,000 breast cancer patients across 12 distinct datasets, incorporating both proprietary clinical data and single-cell data from 7 patients, accounting for a total of 43,095 cells. By employing an integrative strategy that utilized 10 machine learning algorithms across 108 unique combinations, the research scrutinized 100 existing breast cancer signatures. Empirical validation was sought through immunohistochemistry assays, alongside explorations into potential immunotherapeutic and chemotherapeutic avenues. Results: The investigation successfully identified six genes related to vascular mimicry from multi-center cohorts, laying the groundwork for a novel predictive model. This model outstripped the prognostic accuracy of traditional clinical and molecular indicators in forecasting recurrence and mortality risks. High-risk individuals identified by our model faced worse outcomes. Further validation through IHC assays in 30 patients underscored the model's extensive applicability. Notably, the model unveiled varying therapeutic responses; low-risk patients might achieve greater benefits from immunotherapy, whereas high-risk patients demonstrated a particular sensitivity to certain chemotherapies, such as ispinesib. Conclusions: This model marks a significant step forward in the precise evaluation of breast cancer prognosis and therapeutic responses across different patient groups. It heralds the possibility of refining patient outcomes through tailored treatment strategies, accentuating the potential of machine learning in revolutionizing cancer prognosis and management.

Prognostic prediction for HER2-low breast cancer patients using a novel machine learning model

Evaluation of Machine Learning Algorithms for the Prognosis of Breast Cancer from the Surveillance, Epidemiology, and End Results Database

Development and validation of machine learning models for predicting HER2-zero and HER2-low breast cancers

Machine learning‐based model constructed from ultrasound radiomics and clinical features for predicting HER2 status in breast cancer patients with indeterminate (2+) immunohistochemical results

Ultrasound-based radiomics nomogram for predicting HER2-low expression breast cancer

Breast Cancer Prognosis Using a Machine Learning Approach

Prognostic prediction of breast cancer patients using machine learning models: a retrospective analysis

Performance evaluation of ML models for preoperative prediction of HER2-low BC based on CE-CBBCT radiomic features: A prospective study

Machine learning models for differential diagnosing HER2-low breast cancer: A radiomics approach

A radiomics-based interpretable machine learning model to predict the HER2 status in bladder cancer: a multicenter study

Deciphering breast cancer prognosis: a novel machine learning-driven model for vascular mimicry signature prediction

Application of Machine Learning Algorithms to Predict Lymph Node Metastasis in Early Gastric Cancer

Breast Cancer Prediction Based on Machine Learning

Machine learning-based models for the prediction of breast cancer recurrence risk

Machine learning applications in breast cancer survival and therapeutic outcome prediction based on multi-omic analysis

Development of a Machine Learning-Based Prognostic Model for Hormone Receptor-Positive Breast Cancer Using Nine-Gene Expression Signature

Novel models by machine learning to predict prognosis of breast cancer brain metastases

Machine learning-informed liquid-liquid phase separation for personalized breast cancer treatment assessment

A Multicenter Study of the Clinicopathological Characteristics and a Risk Prediction Model of Early-Stage Breast Cancer with Hormone Receptor-Positive/human Epidermal Growth Factor Receptor 2-Low Expression

Development and validation of a prognostic model for HER2-low breast cancer to evaluate neoadjuvant therapy

Predicting HER2 Status in Breast Cancer on Ultrasound Images Using Deep Learning Method